Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
Arcus Biosciences, Inc. beats earnings expectations. Reported EPS is $-0.05, expectations were $-0.97. Arcus Biosciences, Inc.
Arcus Biosciences Inc. (RCUS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Woodline Partners Michael Rockefeller And Karl Kroeker | 4,245,221 | $64,654,716 | +48% | 0.61% |
| 2. | Point72 Asset Management Steve Cohen | 1,833,851 | $27,929,551 | -5% | 0.07% |
| 3. | Suvretta Capital Management Aaron Cowen | 957,304 | $14,579,740 | 0.53% | |
| 4. | Decheng Capital Min Cui | 869,790 | $13,246,902 | 4.05% | |
| 5. | Citadel Investment Group Ken Griffin | 467,163 | $7,114,893 | +32% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.00 | 15,238,095 | Large Shareholder | 30,061,124 | 2024-01-29 | Filing | |
| $19.26 | 1,010,000 | Large Shareholder | 14,823,029 | 2023-06-28 | Filing | |
| $31.37 | 4,133 | Director | 7,133 | 2021-04-23 | Filing | |
| $28.35 | 20,000 | Director | 102,106 | 2021-03-31 | Filing | |
| $39.00 | 5,650,000 | Large Shareholder | 13,913,029 | 2021-01-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.97 | 1,357 | Officer | 19,070 | 2024-08-13 | Filing | |
| $17.55 | 11,551 | Officer | 215,253 | 2024-03-27 | Filing | |
| $18.62 | 1,296 | Officer | 226,804 | 2024-03-18 | Filing | |
| $17.84 | 12,153 | Officer | 228,100 | 2024-03-18 | Filing | |
| $20.11 | 34,070 | Officer | 240,253 | 2024-02-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,035,170 | $191,671,750 | 0% | |
| 2. | 4,728,782 | $90,319,736 | 0% | |
| 3. | 4,680,716 | $89,401,676 | 0% | |
| 4. | 4,239,577 | $80,975,921 | 0% | |
| 5. | 1,634,805 | $31,224,776 | 0% |
News See All
Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2023 Earnings Call Transcript
Operator: Hello and welcome to the Arcus Biosciences Full Year/Q4 2023 Earnings Call. My name is Elliot, and I’ll be coordinating your call today. [Operator Instructions].
Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript
Operator: Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions.
Hedge Fund and Insider Trading News: Ken Griffin, Crispin Odey, Starboard Value, Verition Fund Management, Millennium Management, Children's Place Inc (PLCE), MediaAlpha, Inc. (MAX), and More
Activist hedge fund Starboard Value on Thursday urged utility firm Algonquin Power & Utilities (AQN.TO) to sell a majority of its renewable assets to reduce debt and improve earnings.
Trending Stocks on Tuesday: Top 10 Gainers
According to RBC Capital Markets, investors who are bullish about US equities over a course of the "next six months to a year have nearly vanished” as the Federal Reserve tightens its monetary policy...
Hedge Funds Are Selling Arcus Biosciences, Inc. (RCUS)
While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get cautious...
10 Best Biotech Stocks to Buy According to Mark Lampert's Biotechnology Value Fund
In this article, we discuss the 10 best biotech stocks to buy according to Mark Lampert.
Hedge Funds Are Cashing Out Of Arcus Biosciences, Inc. (RCUS)
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Is Arcus Biosciences, Inc. (RCUS) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Fund and Insider Trading News: Carl Icahn, Steve Cohen, Alden Global Capital, Archegos Capital, Apollo Global Management, Arcus Biosciences Inc (RCUS), Starbucks Corporation (SBUX), and More
NEW YORK (Reuters Breakingviews) - DEALING AND WHEELING. Carl Icahn’s listed fund has a new leading man.